GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Down 62.4% in March

GT Biopharma, Inc. (NASDAQ:GTBP) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 94,200 shares, a drop of 62.4% from the February 28th total of 250,300 shares. Based on an average daily volume of 852,200 shares, the short-interest ratio is currently 0.1 days. Approximately 4.2% of the company’s shares are short sold.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Roth Capital raised GT Biopharma to a “strong-buy” rating in a research report on Monday, December 2nd. Roth Mkm initiated coverage on GT Biopharma in a research note on Monday, December 2nd. They issued a “buy” rating and a $11.00 price objective for the company.

GT Biopharma Stock Up 4.3 %

NASDAQ:GTBP traded up $0.10 on Friday, reaching $2.40. 15,611 shares of the company’s stock were exchanged, compared to its average volume of 579,004. The firm has a market capitalization of $6.09 million, a price-to-earnings ratio of -0.34 and a beta of 0.59. GT Biopharma has a 52-week low of $1.72 and a 52-week high of $10.66. The business has a fifty day moving average of $2.29 and a 200-day moving average of $2.50.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.